Introduction: In the realm of drug discovery, the traditional approach of developing inhibitors that target active sites of disease-related proteins presents limitations, leaving a vast portion of disease-related proteins inaccessible. This uncharted territory, estimated to encompass around 80% of disease-related proteins, is often deemed “undruggable” due to the absence of specific active sites or binding […]
Efforts to develop potent small molecule inhibitors for protein regulation have faced challenges in targeting undruggable proteins due to the limitations of small molecule topology. The emerging strategy of protein degron, which involves molecules or complexes specifically designed to target and catalyze protein degradation, offers a promising solution. Unlike traditional inhibitors, degraders facilitate protein degradation […]
